

CD68+ macrophages were found to be closely associated with tumor cells, PD-L1+ macrophages were found to have the closest interaction with tumor cells. The potential of these cell phenotypes to generate a strongly immunosuppressive microenvironment need to be explored in additional cases.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0547>


548 **CD8+ TISSUE-RESIDENT MEMORY T CELLS ARE TUMOUR REACTIVE AND INCREASE AFTER IMMUNOTHERAPY IN A CASE OF METASTATIC MUCOSAL MELANOMA**

¹Angela Pizzolla*, ¹Simon Keam, ¹Ismael Vergara, ¹Franco Caramia, ¹Minyu Wang, ¹Nikolce Kocovski, ¹ThuNgoc Nguyen, ¹Sean Macdonald, ¹Daniela Tantalò, ¹Pasquale Petrone, ¹Han Xian Aw Yeang, ¹David Gyorki, ¹Alison Wepler, ¹George Au-Yeung, ¹Shahneen Sandhu, ²Maurizio Perdicchio, ¹Grant McArthur, ¹Tony Papenfuss, ¹Paul Neeson. ¹Peter MacCallum Cancer Centre, Melbourne, Australia; ²F. Hoffmann - La Roche Ltd, Seattle, WA, United States

Background Mucosal melanoma is a rare subtype of melanoma originating from mucosal tissues,¹ metastases are very aggressive and respond poorly to therapy, including immune checkpoint inhibitors (ICI) such as anti-CTLA4 and anti-PD1 antibodies.^{2–5} CD8+ T cells constitute the most abundant immune infiltrate in metastatic melanoma, of which the Tissue Resident Memory subset (TRM) is of particular interest.⁶ CD8+ TRM cells express the highest levels of immune checkpoint receptors, proliferate in response to ICI and correlate with longer disease-free and overall survival.^{6–8} The immune landscape in mucosal melanoma remains poorly characterized. We aimed to: 1) phenotype CD8+ T cells and TRM infiltrating metastatic mucosal melanoma, 2) characterize the clonality of TRM in relation to other CD8+ T cell subsets and 3) define the capacity of CD8+ T cells and TRM to respond to melanoma cells and to in vivo and in vitro anti-PD1 treatment.

Methods We investigated the CD8+ T and TRM cells infiltrating two temporally- and spatially-distant subcutaneous metastases, these originated from a primary vaginal mucosal melanoma. One metastasis was excised prior to anti-PD1 treatment and one was anti-PD1 refractory, having progressed on treatment. We used mass cytometry and single-cell RNA and TCR sequencing to characterise the phenotype and clonality of the T cells, multiplex immunohistochemistry to define their spatial relationship with tumour cells and other T cells, and functional assays to determine TRM response to tumour cells (figure 1).

Results CD8+ TRM frequency increased with time and anti-PD1 treatment, forming clusters at the tumour margin. T cells in the anti-PD1 refractory lesion were more activated than T cells in the first tumour and were bound by anti-PD1 antibody in vivo. T cells could not be stimulated by anti-PD1 directly ex vivo. Both metastatic lesions shared common T cell clusters including TRM. Furthermore, TRM in each tumour shared T cell clones, suggesting the presence of common antigens between metastatic sites. Indeed, the two metastases had a similar mutational profile. In vitro expanded tumour infiltrating lymphocytes from both lesions recognized tumour cells from both lesions and the same neoantigen generated from a single point mutation in the gene CDKN1C. Finally, tumour cells stimulated TRM cells more robustly than other T cell subsets.



Abstract 548 Figure 1 Graphical depiction of the methods used to characterise T cells in mucosal metastatic melanoma

Conclusions In this patient with vaginal mucosal melanoma, subsequent melanoma metastases of clonal origin attracted CD8+ T cells of similar specificity, among which TRM cells responded more vigorously to tumour cells than other T cell subsets.

Acknowledgements The authors would like to acknowledge imCORE La Hoffmann- Roche Ltd. for funding.

Ethics Approval Patients diagnosed with stage 3 or 4 metastatic melanoma and undergoing clinically indicated surgery were enrolled in prospective studies approved by the Peter MacCallum Cancer Centre human ethics research committee (13/141). All experimental protocols have been approved and clinical data has been collected prospectively.

REFERENCES

- Carvajal RD, Hamid O, Ariyan C. Mucosal Melanoma. [cited 2020 Apr 1]; Available from: www.uptodate.com/contents/mucosal-melanoma
- Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, et al. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. *Eur J Cancer Oxf Engl* 1990;2014 Jan;**50**(1):121–7.
- Postow MA, Luke JJ, Bluth MJ, Ramaia N, Panageas KS, Lawrence DP, et al. Ipilimumab for patients with advanced mucosal melanoma. *The Oncologist* 2013 Jun;**18**(6):726–32.
- D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol Off J Am Soc Clin Oncol*. 2017 Jan 10;**35**(2):226–35.
- Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. *Br J Cancer* 2018;**119**(6):670–4.
- Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pomputpong N, Mai Z, et al. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. *JCI Insight* [Internet]. 2016 Dec 22 [cited 2019 Apr 24];1(21). Available from: <https://insight.jci.org/articles/view/88955>
- Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103+ Tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti-PD-1 treatment. *Clin Cancer Res Off J Am Assoc Cancer Res* 2018 Jul 1;**24**(13):3036–45.
- Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nat Med* 2018 Jul;**24**(7):986–93.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0548>

549 **CHARACTERIZING DOUBLE POSITIVE T CELLS IN THE TUMOR MICROENVIRONMENT: A TALE OF PROMISCUOUS CELL FATES**

¹Sara Schadt*, ¹Andrew Chow, ²Heng Pan, ¹Levi Mangarin, ¹Roberta Zappasodi, ¹Mathieu Gigoux, ²David Redmond, ¹Daniel Hirschhorn-Cymerman, ¹Sadna Budhu, ¹Hong Zhong, ¹Xia Yang, ²Olivier Elemento, ¹Jedd Wolchok, ¹Taha Merghoub. ¹MSKCC, New York, NY, USA; ²WCMC, New York, NY, USA